

Index

A

Adverse effects, 8
Algometry, 77–83
Antimicrobial therapy, 23
Aortic valve regurgitation, 29–32
Apnea-hypopnea index, 12, 14
Arrhythmias, 49, 53–60
Autoimmunity, 71–75

C

Candida spp., 63–69
Cardiac involvement, 28, 31, 32
Chronic kidney insufficiency, 11–17
Cognitive functioning, 4, 5, 7, 8
Comorbidities, 3, 5, 7–9, 12, 13, 15–17, 24, 48–51, 55, 56
Computed tomography, 37, 39, 40
COPD, 16, 17, 24, 46–51, 53–60
COPD exacerbation, 50, 54, 56–60
Cyclosporin A, 65, 66, 68, 69

D

Diagnostics, 36, 39–41, 78

E

ECG monitoring, 57
Echocardiography, 28–30, 32
Exacerbations, 46–51, 54–60

F

Fever of unknown origin, 35–42

G

GOLD guidelines, 45–51, 58
Granulomatosis with polyangiitis, 27–32

H

Health prevention, 82
Hydrolytic enzyme activity, 66, 68
Hypothyroidism, 15, 16, 72–75

I

Immunosuppressive treatment, 29, 31, 66, 68, 69
Infection, 16, 19–24, 36–42, 46, 50, 54, 64, 65, 69

K

Karyotype, 72–75
Klebsiella pneumoniae ESBL+, 19–24

L

Lung lesions, 35–42

M

Malignance, 2, 22, 24
Massage, 77–83
Mortality, 1–24, 28, 47–50, 54–57, 59, 60
Multidrug resistance, 23

N

Nephrotic syndrome, 63–69
Non-small cell lung cancer (NSCLC), 2, 7–9
Nosocomial infections, 20
NSCLC. *See* Non-small cell lung cancer (NSCLC)

O

Obstructive sleep apnea, 11–17
Oral candidiasis, 65, 67, 68

P

Pain threshold, 79–82
Performance status, 3, 5, 7, 8
Physical functioning, 2, 5, 8
Prognosis, 2, 9, 20

Q

Quality of life, 1–9, 46, 50

R

Relaxation, 30, 78–82
Remission, 28–32, 37

Renal function, 15, 37

Risk factors, 2, 12, 15, 20–24, 39, 40, 46, 50, 54, 55, 57, 58, 60

S

Socioeconomic factors, 8

Spirometry, 46, 51

Symptoms, 2–9, 12, 13, 17, 29, 30, 32, 40, 41, 46–48, 50, 51, 82

T

Thyroid disease, 16, 75

Turner syndrome, 71–75

V

Vasculitis, 28, 36, 37, 40, 41

W

White-collar workers, 77–83